AVIEW LCS vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW LCS

by Coreline Soft

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

AVIEW LCS is an AI-powered solution for comprehensive cardiopulmonary assessment using CT scans, focusing on lung nodule detection, COPD, and coronary artery calcification. Tempus ECG-AF, conversely, is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients at increased risk of developing atrial fibrillation. While both fall under Cardiology AI, they utilize different diagnostic modalities and target distinct cardiac conditions, making them adjacent rather than direct competitors.

Choose AVIEW LCS if…

Choose AVIEW LCS if your primary need is a comprehensive, AI-powered solution for multi-modal cardiopulmonary assessment from low-dose CT scans. This tool is ideal for radiology departments and oncology/pulmonology practices seeking automated detection and analysis of lung nodules, emphysema quantification, and coronary artery calcification scoring to streamline lung cancer screening and diagnostic workflows.

View AVIEW LCS →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your objective is to proactively identify patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within the next 12 months, using standard 12-lead ECG recordings. This AI algorithm is best suited for cardiology, geriatrics, and internal medicine practices looking to support earlier intervention and follow-up for high-risk elderly patients without pre-existing AF or cardiac devices.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW LCS	Tempus ECG-AF
Pricing	Subscription or one-off payment	Contact vendor
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW LCS

AVIEW LCS emphasizes integrated, fully automatic analysis and streamlining radiology workflows, including automated report generation and diverse deployment options (cloud, hybrid, local). This suggests a highly user-centric design that integrates seamlessly into existing clinical environments.

Clinical Value

AVIEW LCS

AVIEW LCS provides comprehensive analysis for lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy across multiple critical conditions. This multi-modal assessment from one scan offers broader clinical utility compared to Tool B's focused AF risk prediction.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF explicitly outlines CMS reimbursement codes (CPT 0764T and CPT 0765T to APC 5734) and a Medicare rate of $128.90, effective January 1, 2025, offering clear financial pathways for adoption. AVIEW LCS only states 'contact for pricing,' lacking this crucial transparency.

Enterprise Readiness

AVIEW LCS

Both tools are FDA-cleared, HIPAA compliant, and have BAAs. However, AVIEW LCS offers a wider array of deployment options (cloud, hybrid, local, virtualized) and explicit integration with PACS/RIS, making it more adaptable to diverse enterprise IT infrastructures and existing radiology workflows.

Innovation

AVIEW LCS

AVIEW LCS demonstrates innovation through its integrated, multi-modal analysis from a single CT scan, providing comprehensive assessment for lung cancer, COPD, and CAC with advanced quantification features like 3D segmentation and volume quantification. While Tempus ECG-AF's predictive AI for future AF risk is innovative, AVIEW LCS offers a broader range of integrated diagnostic capabilities from one imaging modality.

Support & Docs

Tie

The provided structured facts and web searches did not yield specific comparative information regarding the depth, availability, or quality of support and documentation for either AVIEW LCS or Tempus ECG-AF. Tempus does provide a support email and phone number.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW LCS	Tempus ECG-AF
Tool Name	AVIEW LCS	Tempus ECG-AF
Company	Coreline Soft Co.	Tempus AI, Inc.
Primary Function	AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from low-dose CT scans.	AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Key AI Analysis	Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans.	AI-based algorithm for 12-lead ECG analysis, detects signs associated with new onset Atrial Fibrillation (AF) within 12 months.
Target Patient Population	Not specified	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Specialties	Cardiology, Oncology, Pulmonology, Radiology	Cardiology, Geriatrics, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of AVIEW LCS and Tempus ECG-AF?

AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules, lung cancer screening, COPD, and coronary artery calcification from low-dose CT scans. Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within the next 12 months.

What types of patient data are required as input for each of these AI tools?

AVIEW LCS requires low-dose CT scans for its comprehensive cardiopulmonary assessment. Tempus ECG-AF utilizes 12-lead ECG recordings, specifically compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.

Are there specific patient populations or conditions for which each tool is designed or has limitations?

AVIEW LCS is designed for general lung cancer screening and cardiopulmonary assessment. Tempus ECG-AF is intended for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

Is there specific information regarding reimbursement for either of these AI tools?

Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T mapping to APC 5734, at a Medicare rate of $128.90 effective January 1, 2025. The provided information for AVIEW LCS does not specify reimbursement details.

What specific diagnostic insights or reports do these tools provide?

AVIEW LCS provides automated lung nodule detection and analysis, Lung-RADS classification, nodule volume quantification, emphysema quantification, and coronary artery calcification scoring, along with comprehensive report generation. Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, with results interpreted in conjunction with other diagnostic information and clinical history.